The potential of Sareum's SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19

Find out more large-arrow.png


Sareum has an innovative pipeline of drug development candidates.

Find out more large-arrow.png


BioTrinity, June 2021 (Slides)
IMC Half Year Results, Apr 2021 (Slides)
LSX World Congress, Feb 2021 (Video)
IMC Full Year Results, Oct 2020 (Slides)

  • @Sareumplc Latest tweet

    RT @HybridanLLP: Good to see Sareum's research on TYK2 as an oncology target referenced here. We see Sareum as a frontrunner in this space… via @Sareumplc
    View more